On October 27, 2021 ZAP Surgical Systems, Inc. reported an agreement to bring its advanced ZAP-X Gyroscopic Radiosurgery platform to the Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France (Press release, ZAP Surgical Systems, OCT 27, 2021, View Source [SID1234592055]). As part of the renown American Hospital of Paris, CCPSC will be the first in France to offer the latest advance in radiosurgical brain tumor treatments. First patient treatments with ZAP-X at CCPSC are estimated to begin the Fall of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stereotactic radiosurgery (SRS) is a well-established procedure for the non-invasive treatment of many primary and metastatic brain tumors, as well cranial functional and vascular disorders including trigeminal neuralgia and arteriovenous malformations. Often considered an alternative to costly and invasive surgical procedures, SRS is a non-invasive outpatient procedure that often provides superior outcomes, yet requires no surgical incision, and little to no patient recovery period.

"A significant percentage of cancer patients develop brain metastases during the course of their disease," said Eric Duret, General Manager of CCSPC. "As this population continues to grow with improving cancer survival, having the most advanced radiosurgery option available to our patients was imperative."

The ZAP-X system uses unique gyroscopic mobility to direct radiosurgical beams from hundreds of angles to precisely concentrate radiation on the tumor target. This pioneering approach supports the clinical objective of protecting healthy brain tissue and patient cognitive function, and when needed, enable future potential SRS re-treatments without the unnecessary risks associated with other radiation delivery techniques.

ZAP-X is additionally recognized for being the first and only vault-free and cobalt-free dedicated SRS delivery system, thereby eliminating the costs to build expensive shielded radiation treatment rooms, and removing the need to maintain, secure and regularly replace live radioactive isotopes.

For more about the ZAP-X Gyroscopic Radiosurgery platform, please visit: View Source Detailed system overview animations can be found at View Source

On October 27, 2021 Monteris Medical, the leader in MR-guided laser interstitial thermal therapy (LITT or laser ablation), reported that Cigna, a global health services company and one of the largest commercial payors in the United States, has released a national coverage policy supporting the use of LITT for people with brain tumors and drug-resistant epilepsy (Press release, Monteris Medical, OCT 27, 2021, View Source [SID1234592020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The medical coverage policy by Cigna considers LITT medically necessary in the treatment of drug-resistant epilepsy and symptomatic brain tumors and radiation necrosis when medical necessity is met, and the patient is not suitable for open brain surgery.

"Many patients with brain tumors face situations in which traditional, open surgery is neither possible, nor the preferred approach. This policy decision by Cigna offers appropriate patients greater access to a targeted, minimally invasive technology that can positively impact their care and improve their quality of life," said Dr. Peter Fecci, director of the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University School of Medicine in Durham, N.C.

A growing body of peer-reviewed clinical evidence continues to show medical advantages of minimally invasive, MR-guided laser ablation technology due to decreased morbidity, faster recovery time, shorter hospital and intensive care stay, and an ability to access lesions not amenable to open surgery. Laser ablation also represents an alternative to surgery for patients with significant comorbidities.

"Cigna and other national payors have progressively widened access to care for the patients we serve. This policy announcement is the latest in a continuum of advancements for LITT, establishing its position in the care pathway for patients and their families afflicted by brain tumors and epilepsy," said Martin J. Emerson, president and chief executive officer of Monteris Medical.

The Cigna coverage policy follows recently issued position statements on the use of LITT for epilepsy and brain tumors, respectively, by the major neurosurgical societies, inclusion of LITT in guidelines issued by the National Comprehensive Cancer Network, and Category Level 1 CPT codes approved by the American Medical Association with an effective date of January, 2022.

On October 27, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported a collaboration that will power A.I.-driven computational research for oncology-focused drug discovery and development with Code Ocean, the leading computational research environment for sharing scientific discoveries (Press release, Lantern Pharma, OCT 27, 2021, View Source [SID1234593961]). By leveraging Code Ocean’s Compute Capsule technology, the strategic approach is expected to further power Lantern Pharma’s RADR platform for faster, more collaborative discoveries from billions of RADR data points, as well as data and insights from Lantern’s network of collaborators.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Computational researchers today are challenged with analyzing big data due to too many disparate tools, lack of specialized coding experience, and challenging, cumbersome DevOps processes required to organize and securely share research. Through this collaboration, Lantern Pharma is expected to benefit from significant efficiencies in development time and cost, as well as increased reproducibility from Code Ocean’s platform. The Code Ocean platform will offer an easy to use, collaborative research experience with an integrated development environment, secure repository, and portable Compute Capsule technology for guaranteed reproducibility.

"I’m thrilled to be working with a leading-edge technology partner like Lantern Pharma," said Simon Adar, Co-Founder and CEO of Code Ocean. "This collaboration truly enables large-scale, high-throughput collaboration both internally at Lantern and also with their leading research partners to accelerate the pace of oncology drug discovery."

"It’s clear that science and discovery need to be fully integrated using the latest tools and technologies to reduce costs, speed-up development, and increase probability of success," said Panna Sharma, President & CEO of Lantern Pharma. "We selected Code Ocean as we believe this collaboration will provide our scientists, researchers, data engineers and collaborators with a best-in-class, reproducible and highly secure platform environment to maximize the power and usability of our RADR A.I. platform to improve and enhance the research experience. Bringing together our proprietary A.I. with Code Ocean’s Compute Capsule technology we believe will allow us and other researchers to take collaborative drug development further and faster than ever before."

Lantern leverages advances in machine learning, genomics and artificial intelligence to develop oncology therapies by using its proprietary A.I. platform, RADR, to discover biomarker signatures aimed at helping identify patients more likely to respond to its pipeline of cancer therapeutics. Working within the Code Ocean platform is expected to help increase team productivity and enhance Lantern Pharma’s ability to collaborate more rapidly with industry leading partners, such as the National Cancer Institute, Georgetown University, Johns Hopkins and Fox Chase Cancer Center, within a secure and agile research environment.

The Code Ocean platform does not require the user to be an IT expert to utilize the software properly. By integrating the essential triplet– code, data and a computing environment– Code Ocean offers the most complete platform for computational research that’s on the market. Code Ocean’s unique Compute Capsules provide a fundamentally easier and more efficient way for researchers to create and safely share their work, which is essential to moving science forward. This, combined with Lantern Pharma’s billions of data points and growing library of algorithms designed for oncology drug development, will allow researchers to have faster access to more data than ever before, without being overwhelmed by massive amounts of data management or computational structure.

On October 27, 2021 EpiAxis Therapeutics reported at three conferences this week – Australia Biotech Invest & Partnering 2021; Europe’s largest life science partnering conference, BIO-Europe 2021; and Wholesale Investor’s STEM 2021 Conference (Press release, EpiAxis Therapeutics, OCT 27, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-headlines-three-key-biotech-conferences [SID1234591993]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO of EpiAxis Therapeutics, Dr Jeremy Chrisp, presented at the Australia Biotech Invest & Partnering 2021 earlier this week which is Australia’s premier life sciences investment conference. It’s an interactive digital showcase, designed to foster growth and drive business-to-business investment and collaboration in what continues to be a significant time for life sciences and medical research. The conference was held online on Tuesday, October 26, 2021. Engaging capital with innovation, it was an opportunity for companies to present their technology and story to a network of potential international partners and investors. Investors include those in venture capital, private equity, HNW individuals, research analysts and brokers, as well as industry executives from major global pharmaceutical companies. The program also featured keynote sessions from investment leaders on industry trends and market updates.

The international BIO-Europe 2021 gathering is being held digitally from October 25-28, bringing the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs.

Chrisp will also appear at Wholesale Investor’s STEM 2021 Conference on Thursday, October 28. EpiAxis recently joined Wholesale Investor, Australasia’s leading investment platform for connecting innovative, emerging companies that are looking to raise capital with an active, engaged and growing ecosystem of more than 29,300 high-net-worth investors, fund managers, family offices, PE and VC firms, government bodies and industry participants. The showcase includes everything investors need to capitalise on STEM investment opportunities.

"We are delighted to be presenting at these conferences with our biotech peers to raise the profile of EpiAxis and the importance of epigenetic therapies as a new approach to treating cancer," Chrisp said. "It has also been an excellent opportunity to network with potential investors and familiarise them with our novel approach, which targets cancer stem cells that can evade chemotherapy and immunotherapy, to ‘reprogram’ them back to normal cells."

On October 27, 2021 The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), reported a regular quarterly dividend of $0.07 per share of common stock October 27, 2021 (Press release, PerkinElmer, OCT 27, 2021, View Source [SID1234592031]). This dividend is payable on February 11, 2022 to all shareholders of record at the close of business on January 21, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!